Table 1. Association of nodal metastasis and patient features by data source.
| METABRIC | TCGA | |||||
|---|---|---|---|---|---|---|
| Nodal metastasis present | No | Yes | p-value | No | Yes | p-value |
| (N = 389) | (N = 383) | (N = 293) | (N = 357) | |||
| Race | 0.021 | 0.678 | ||||
| - Asian | 1 (0.3%) | 2 (0.5%) | 20 (6.8%) | 26 (7.3%) | ||
| - Black | 0 (0.0%) | 0 (0.0%) | 40 (13.7%) | 45 (12.6%) | ||
| - missing | 225 (57.8%) | 179 (46.7%) | 22 (7.5%) | 36 (10.1%) | ||
| - Other | 3 (0.8%) | 4 (1.0%) | 0 (0.0%) | 1 (0.3%) | ||
| - White | 160 (41.1%) | 198 (51.7%) | 211 (72.0%) | 249 (69.7%) | ||
| Age at diagnosis (± SD) | 59.1 ± 12.2 | 60.8 ± 14.4 | 0.088 | 58.0 ± 12.4 | 56.1 ± 13.1 | |
| Receptor subtype | 0.572 | 0.043 | ||||
| - missing | 0 (0.0%) | 0 (0.0%) | 29 (9.9%) | 23 (6.4%) | ||
| - HER2 | 28 (7.2%) | 34 (8.9%) | 9 (3.1%) | 21 (5.9%) | ||
| - Luminal | 285 (73.3%) | 282 (73.6%) | 212 (72.4%) | 276 (77.3%) | ||
| - TNBC | 76 (19.5%) | 67 (17.5%) | 43 (14.7%) | 37 (10.4%) | ||
| ER status | 0.708 | 0.102 | ||||
| - missing | 0 (0.0%) | 0 (0.0%) | 17 (5.8%) | 16 (4.5%) | ||
| - negative | 104 (26.7%) | 108 (28.2%) | 88 (30.0%) | 84 (23.5%) | ||
| - positive | 285 (73.3%) | 275 (71.8%) | 188 (64.2%) | 257 (72.0%) | ||
| PR status | 0.171 | 0.324 | ||||
| - missing | 0 (0.0%) | 0 (0.0%) | 19 (6.5%) | 17 (4.8%) | ||
| - negative | 184 (47.3%) | 200 (52.2%) | 110 (37.5%) | 121 (33.9%) | ||
| - positive | 205 (52.7%) | 183 (47.8%) | 164 (56.0%) | 219 (61.3%) | ||
| HER2 status | 0.138 | 0.591 | ||||
| - missing | 0 (0.0%) | 0 (0.0%) | 96 (32.8%) | 114 (31.9%) | ||
| - negative | 336 (86.4%) | 316 (82.5%) | 154 (52.6%) | 180 (50.4%) | ||
| - positive | 53 (13.6%) | 67 (17.5%) | 43 (14.7%) | 63 (17.6%) | ||
| Menopause status | 0.579 | 0.027 | ||||
| - missing | 0 (0.0%) | 1 (0.3%) | 18 (6.1%) | 39 (10.9%) | ||
| - post | 293 (75.3%) | 291 (76.0%) | 213 (72.7%) | 228 (63.9%) | ||
| - pre | 96 (24.7%) | 91 (23.8%) | 62 (21.2%) | 90 (25.2%) | ||
| Tumor size | <0.0001 | <0.0001 | ||||
| - T1 (<20 mm) | 230 (59.1%) | 126 (32.9%) | 115 (39.3%) | 72 (20.2%) | ||
| - T2 (>20 <50mm) | 157 (40.4%) | 234 (61.1%) | 160 (54.7%) | 229 (64.1%) | ||
| - T3&4 (>50 mm) | 2 (0.5%) | 23 (6.0%) | 17 (5.9%) | 56 (15.7%) | ||
| AJCC Stage | <0.0001 | <0.0001 | ||||
| - I | 251 (64.5%) | 3 (0.8%) | 115 (39.2%) | 8 (2.2%) | ||
| - II | 132 (33.9%) | 311 (81.2%) | 173 (59.0%) | 203 (56.9%) | ||
| - III&IV | 6 (1.5%) | 69 (18.0%) | 3 (1.0%) | 129 (36.1%) | ||
| - missing | 0 (0.0%) | 0 (0.0%) | 2 (0.7%) | 17 (4.8%) | ||
Abbreviations: HER2, human epidermal growth factor receptor 2; TNBC, triple negative/basal breast subtype; ER, estrogen receptor; PR, progesterone receptor.
*Tumor size is AJCC TNM staging.